Koyfin Home > Directory > Health Care > Adamas Pharma > Long-term Debt / Equity

Adamas Pharma Long-term Debt / Equity Chart (ADMS)

Adamas Pharma annual/quarterly Long-term Debt / Equity from 2017 to 2020.
  • Adamas Pharma Long-term Debt / Equity for the quarter ending June 06, 2020 was $-548m a 222.64% decrease of -1,219m year over year
  • Adamas Pharma Long-term Debt / Equity for the last 12 months ending June 06, 2020 was $-548m a 222.64% decrease of -1,219m year over year
  • Adamas Pharma Annual Long-term Debt / Equity for 2019 was $-15,000m a 100.87% decrease of -15,130m from 2018
  • Adamas Pharma Annual Long-term Debt / Equity for 2018 was $131m a -18.79% decrease of -25m from 2017
  • Adamas Pharma Annual Long-term Debt / Equity for 2017 was $155m
Other Ratios Metrics:
  • Adamas Pharma Total Debt / Capital for the quarter ending September 09, 2018 was $50m a -21.13% decrease of -11m year over year
  • Adamas Pharma Other Liabilities for the quarter ending December 12, 2018 was $3m a 76.22% increase of 2m year over year
  • Adamas Pharma Total Debt / Equity for the quarter ending September 09, 2018 was $101m a -53.94% decrease of -54m year over year
View Chart On Koyfin

Quarterly ADMS Long-term Debt / Equity Data

06/2020$-548m
03/2020$-845m
12/2019$-15,000m
09/2019$672m
06/2019$305m
03/2019$200m
12/2018$131m
09/2018$101m
06/2018$78m
03/2018$63m

Annual ADMS Long-term Debt / Equity Data

2019$-15,000m
2018$131m
2017$155m